DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a precision dermatology company that went public through a business combination with Constellation Alpha Capital Corp., a blank-check vehicle sponsored by Constellation Alpha Capital LLC that IPO'd in 2017. Operating in the healthcare diagnostics sector, DermTech develops non-invasive genomic tests for skin conditions, including a flagship assay for early melanoma detection. The company filed an 8-K on May 29, 2019, in the lead-up to the de-SPAC closing later that summer. DMTK subsequently listed on Nasdaq but faced persistent commercial headwinds and filed for Chapter 11 bankruptcy protection in 2024. Sign up for SpacDesk to access complete filing history, deal timelines, and post-merger performance data on DMTK.